¡Ø Ãß¼® ¿¬ÈÞ ÈÞ¹«¾È³» : 2024³â 9¿ù 16ÀÏ(¿ù) ~ 2024³â 9¿ù 18ÀÏ(¼ö)

½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1519789

´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Needle-free Drug Delivery Technology Market by Product, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 44¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 67¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4.56%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇÏ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ È®»ê, °í·É Àα¸ Áõ°¡, ÃÖ±Ù ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ ¹Ù´Ã ¾ø´Â ÁÖ»ç ±â¼ú(NFIT)ÀÇ °³¹ßÀº ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ±âÁ¸ÀÇ ÁÖ»ç ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê°í ȯÀÚ¿¡°Ô ¾à¹°À» Åõ¿©ÇÏ´Â ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¸¶ÀÌÅ©·Î ³ëÁñ Á¦Æ® ÀÎÁ§ÅÍ, °æÇÇ ÆÐÄ¡, ÈíÀÔ±â, ÀÏȸ¿ë Ä«Æ®¸®Áö ÀÎÁ§ÅÍ, ºñ°­ ½ºÇÁ·¹ÀÌ, ÃÊÀ½ÆÄ µîÀÌ Æ÷ÇԵ˴ϴÙ. À̵éÀº ¿¹¹æÁ¢Á¾, Àν¶¸° Åõ¿©, ÅëÁõ °ü¸®, È£¸£¸ó ¿ä¹ý, ¾Ë·¹¸£±â, ¾Ï, È£Èí±â Áúȯ ¹× ±âŸ ¸¸¼ºÁúȯ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ¹Ù´ÃÀ» »ç¿ëÇÏ´Â Àü´Þ ½Ã½ºÅÛ°ú ºñ±³ÇÏ¿© ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ÅëÁõÀ» ÁÙÀÌ°í, ºÒÆíÇÔ°ú ºÒ¾ÈÀ» ÃÖ¼ÒÈ­Çϸç, ÆíÀǼºÀ» ³ôÀÌ°í, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ°í, º¹¿ë·®À» ¸ÂÃãÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ºÎ»ó°ú °¨¿°ÀÇ À§ÇèÀ» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´õ ºü¸¥ ¾à¹°Àü´ÞÀ» ÅëÇØ ¾à¹°ÀÇ Èí¼ö¸¦ ÃËÁøÇÏ°í ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϸç Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº À¯ÇØ Æó±â¹° ¹ß»ýÀ» ÃÖ¼ÒÈ­ÇÏ°í, Á¦Á¶½Ã ¹èÃâÀ» ÁÙÀ̸ç, Á¦Ç° Æó±â Çʿ伺À» ¾ø¾Ö±â ¶§¹®¿¡ ȯ°æ ģȭÀûÀÔ´Ï´Ù.

¹«Ä§¾à Àü´Þ ±â¼ú ½ÃÀå µ¿Çâ :

´ç´¢º´, ¾Ï, Å©·Ðº´, ´Ù¹ß¼º °æÈ­Áõ, °üÀý¿°, °ñ´Ù°øÁõ, ½ÉÇ÷°ü Áúȯ(CVDs)°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ÅëÁõÀ̳ª ºÒÆíÇÔ ¾øÀÌ ¸¸¼ºÁúȯ ȯÀÚ¿¡°Ô Àν¶¸°°ú ¾à¹°À» Àü´ÞÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀ̸ç ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃÅ°´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ º¹¾à ¼øÀÀµµ Çâ»ó, ¾à¹° Èí¼ö Áõ°¡, Ä¡·á È¿°ú Çâ»ó, ÁÖ»ç¹Ù´Ã·Î ÀÎÇÑ ÇÕº´Áõ ÃÖ¼ÒÈ­¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ±â¼úÀÇ º¸±ÞÀÌ ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ±Ù ·¹ÀÌÀú¸¦ ÀÌ¿ëÇØ ÇǺο¡ ¹Ì¼¼ÇÑ ¾à¹°À» Á¤¹ÐÇÏ°Ô ºÐ»çÇÏ´Â ¹«Ä§ÁÖ»ç ±â¼ú(NFIT)ÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀεµÀûÀÌ°í ½ºÆ®·¹½º ¾ø´Â ¹æ½ÄÀ¸·Î µ¿¹°¿¡°Ô ¹é½Å, ¾à¹°, ¸¶ÃëÁ¦¸¦ Åõ¿©Çϱâ À§ÇØ µ¿¹° ÀÇ·á ºÐ¾ß¿¡¼­ ±â¼ú È°¿ëÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿Í´Â º°µµ·Î, ¹Ù´Ã ¾ø´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í ÷´Ü ±â¼ú °³¹ßÀ» Áö¿øÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ ±¸»óÀÇ ½ÃÇàÀº ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ¹àÀº Àü¸ÁÀ» Á¦½ÃÇÏ°í ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â Àü¿°º´ À¯ÇàÀ¸·Î ÀÎÇÑ ¹é½Å ¼ö¿ä Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß È°µ¿, ¹«Ä§Åõ ¾à¹°Àü´Þ ±â¼úÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÎ½Ä Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • COVID-19°¡ Àü ¼¼°è ¹«Ä§Åõ ¾à¹°Àü´Þ ±â¼ú ½ÃÀå¿¡ ¹ÌÄ£ ¿µÇâÀº?
  • ¼¼°è ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
    • Åé´Ù¿î ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ÈíÀÔ±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¦Æ® ÀÎÁ§ÅÍ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½ÅÇü ´Ïµé
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °æÇÇÆÐÄ¡
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¹é½Å Àü´Þ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÅëÁõ °ü¸®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àν¶¸° Åõ¿©
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø°ú Áø·á¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ȨÄɾî ȯ°æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¶»ç½Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Çмú
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

  • °³¿ä
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • Akra Dermojet
    • Antares Pharma Inc.(Halozyme Therapeutics Inc.)
    • Crossject
    • Mika Medical Co.
    • PharmaJet
    • Portal Instruments Inc.
KSA 24.08.16

The global needle-free drug delivery technology market size reached US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.56% during 2024-2032. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.

Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.

Needle-free Drug Delivery Technology Market Trends:

The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn's disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients' quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, application, and end user.

Product Insights:

Inhaler

Jet Injector

Novel Needles

Transdermal Patch

Others

The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.

Application Insights:

Vaccine Delivery

Pain Management

Insulin Delivery

Others

A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.

End User Insights:

Hospitals and Clinics

Homecare Settings

Research Laboratories

Academics

Others

A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global needle-free drug delivery technology market?
  • 2. What is the expected growth rate of the global needle-free drug delivery technology market during 2024-2032?
  • 3. What are the key factors driving the global needle-free drug delivery technology market?
  • 4. What has been the impact of COVID-19 on the global needle-free drug delivery technology market?
  • 5. What are the key regions in the global needle-free drug delivery technology market?
  • 6. Who are the key players/companies in the global needle-free drug delivery technology market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Needle-free Drug Delivery Technology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Inhaler
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Jet Injector
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Novel Needles
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Transdermal Patch
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Vaccine Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pain Management
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Insulin Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Users

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare Settings
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Academics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Akra Dermojet
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Antares Pharma Inc. (Halozyme Therapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Crossject
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Mika Medical Co.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 PharmaJet
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Portal Instruments Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦